Development of intraarterial infsuion of micellar nanoparticles for unresectable pancreatic cancer

• Project/Area Number: 18K07640
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Nara Medical University
• Principal Investigator: Tanaka Toshihiro 奈良県立医科大学, 医学部, 教授 (70326338)
• Co-Investigator(Kenkyū-buntansha): 庄 雅之 奈良県立医科大学, 医学部, 教授 (50364063)
• Project Period (FY): 2018-04-01 – 2022-03-31
• Project Status: Completed (Fiscal Year 2021)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2020: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
• Keywords: インターベンショナル・ラジオロジー / 膵癌 / 動注療法 / interventional radiology / Interventional Radiology

Outline of Final Research Achievements

A rat pancreatic cancer model was created and hemodyamics and intraarterial blood distribution were confirmed by dine injection and CT during arteriography. Micellar nanoparticles demonstrated higher tumor tissue concentration at 6-24 hours after injection compared with intraarterial irinotecan injection. Micellar nanoparticles could be a promising intraarterial drug delivery system to achieve high tumor response with reducing adverse events.

Academic Significance and Societal Importance of the Research Achievements

膵癌は予後不良な疾患で国内の死亡数は今なお漸増し現在でも根治が最も困難な癌腫の一つであるとされている。切除不能膵癌に対する化学療法には限界があり、新規治療法の開発が望まれる。本研究は、膵動注療法における新規薬剤の開発を目的とし、ラット膵癌モデルにおいて、ミセル化ナノ粒子が膵癌の治療効果を高め、副作用の低減が期待できることが示された。